Intellia Therapeutics (NTLA) said Wednesday it has named Edward Dulac its chief financial officer, effective July 22.
Dulac will succeed Glenn Goddard, who is stepping down on Sunday, the company said.
Dulac most recently served as Fate Therapeutics' (FATE) CFO.
Price: 24.35, Change: +0.35, Percent Change: +1.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments